Myriad Genetics, a molecular diagnostic company which develops products to treat cancer, has chosen Topin & Associates to support marketing of its molecular diagnostic product, OnDose Dose Optimization Technology.
OnDose utilizes proprietary technology to measure a patient’s exposure to the chemotherapy drug 5-Fluorouracil (5-FU) which provides information with which a physician can optimize the dose of 5-FU to help maximize efficacy and reduce toxicity.
Topin & Associates, along with its educational partner Advanced Clinical Concepts (ACC), has been assigned responsibility for a new strategic communications program that encompasses medical education, promotion and sales force engagement initiatives.
Myriad Genetics Personalized Medicine Group marketing manager Brett Jensen said with OnDose, oncologists can monitor therapeutic drug levels of 5-FU during a colorectal cancer patient’s chemotherapy cycle, adjusting the inter- and intra-patient variability in 5-FU utilization.
Topin & Associates president Al Topin said current dosing is based on body surface area (BSA), which does not account for 5-FU variability between patients and in the same patient from cycle to cycle.